Russell Frank Company’s Neurocrine Biosciences NBIX Stock Holding History

Russell Frank Company’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.35M	Sell	34,054 -19,304	-36%	-$766K	﹤0.01%	2045
2015 Q4	$3.01M	Buy	53,358 +5,148	+11%	+$262K	0.01%	1580
2015 Q3	$1.92M	Buy	48,210 +7,202	+18%	+$348K	﹤0.01%	1864
2015 Q2	$1.96M	Buy	41,008 +40,390	+6,536%	+$1.71M	﹤0.01%	1984
2015 Q1	$25K	Buy	+618	New	+$22.1K	﹤0.01%	2867
2013 Q4	–	Sell	-8,230	Closed	-$93K	–	2951
2013 Q3	$93K	Sell	8,230 -156,260	-95%	-$2.15M	﹤0.01%	2970
2013 Q2	$2.2M	Buy	+164,490	New	+$2.02M	﹤0.01%	1712

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Russell Frank Company's NBIX Position: Q1 2016 in Review

Russell Frank Company reduced its Neurocrine Biosciences (NBIX) stake by 36% in Q1 2016, selling an estimated $766K and leaving 34,054 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Russell Frank Company first reported a position in NBIX in Q2 2013 and has held it in 7 quarters since. The position peaked at $3.01M in Q4 2015. 212 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

Russell Frank Company held 34,054 shares of Neurocrine Biosciences worth $1.35M as of Q1 2016.
Russell Frank Company sold 19,304 Neurocrine Biosciences shares in Q1 2016, an estimated $766K.
Neurocrine Biosciences made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2045 holding.
Russell Frank Company first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 7 quarters since.
Russell Frank Company's Neurocrine Biosciences position peaked at $3.01M in Q4 2015.
212 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.